Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nonapeptide-1 (also known as Melanostatine-5) is a synthetic biomimetic nonapeptide that acts as a selective, competitive antagonist of the melanocortin-1 receptor (MC1R). By blocking the binding of alpha-melanocyte-stimulating hormone (α-MSH) to MC1R on melanocytes, it inhibits the downstream cAMP/PKA signaling pathway, leading to the downregulation of microphthalmia-associated transcription factor (MITF) and key melanogenic enzymes such as tyrosinase. This prevents the hyperproduction of melanin and reduces skin pigmentation. Nonapeptide-1 is widely used as a skin-brightening and tone-correcting active ingredient in cosmetic formulations and is also utilized as a research tool in skin biology and pigmentation studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nonapeptide-1.